PAVmed
PAVM
60 hedge funds and large institutions have $3.67M invested in PAVmed in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 4 closing their positions.
550% more call options, than puts
Call options by funds: $39K | Put options by funds: $6K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
9% more funds holding
Funds holding: 55 → 60 (+5)
0.01% more ownership
Funds ownership: 0.02% → 0.02% (+0.01%)
3% less capital invested
Capital invested by funds: $3.78M → $3.67M (-$113K)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$618K |
| 2 |
First Manhattan
New York
|
+$345K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$36.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$23.4K |
| 2 |
Millennium Management
New York
|
-$20.9K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$16.3K |
| 4 |
Morgan Stanley
New York
|
-$8.22K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$7.6K |
PAVM Hedge Fund Activity: Q3 2023 in Review
60 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q3 2023, worth a combined $3.67M — down 3% from $3.78M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PAVM positions and 4 closed out — a net gain of 5 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Ayrton Capital, adding an estimated $618K. The largest seller was Bank of New York Mellon, cutting an estimated $23.4K.
- 60 institutional investors held PAVmed (PAVM) as of Q3 2023, up from 55 in Q2 2023.
- Funds reported $3.67M of PAVmed stock for Q3 2023, down 3% quarter-over-quarter.
- 9 funds opened new PAVmed positions in Q3 2023 and 4 closed out, a net change of +5 holders.
- The largest PAVmed buyer in Q3 2023 was Ayrton Capital, an estimated $618K added.
- The largest PAVmed seller in Q3 2023 was Bank of New York Mellon, an estimated $23.4K sold.
Based on aggregated 13F filings for Q3 2023.